WILEX AG successfully completes capital increase
Munich, Germany, 25 April 2016 – The Executive Management Board of WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE and ISIN DE000A169P97 / WL6J / FSE) today decided – with the Supervisory Board’s approval – to set the final scope of the rights issue to be executed to a total of 2,248,272 new shares.
WILEX’s shareholders exercised their subscription and additional subscription rights for 1,074,845 new no par value bearer shares at a price of EUR 1.84 per share by the end of the subscription period on 22 April 2016. Thereby, shareholders exercised subscription rights for a total of 1,035,286 new shares. This meant that 1,212,986 new shares were available for additional subscription by shareholders, of which 39,559 new shares were allocated to the shareholders through their custodian banks in connection with the capital increase. Those 1,173,427 new shares not subscribed as part of the offer to exercise subscription and additional subscription rights were taken over for subscription by the main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany, by way of a private placement at the same price of EUR 1.84.
Accordingly, this capital increase will lift the Company’s share capital by EUR 2,248,272, from EUR 10,679,292.00 to EUR 12,927,564.00, once its execution has been entered in the Commercial Register.
WILEX AG plans to use the expected gross proceeds from the rights issue of EUR 4.13 million to finance the further development of the platform technology for Antibody-Targeted Amanitin Conjugates (ATAC), to build an own ATAC product pipeline against cancer diseases and to expand the customer-specific research business.
The subscribed and allotted shares are expected to be delivered on 29 April 2016, but no earlier than after their admission to trading on the Regulated Market (Prime Standard). The new shares are due to be included in trading on 29 April 2016. All new shares carry dividend rights from 1 December 2015. Given this difference in dividend rights, the new shares will be traded separately under the ISIN DE000A169P97 / WKN A16 9P9 until the planned inclusion in the Company’s current listing, which will take place after the Annual General Meeting adopting resolutions regarding the 2014/2015 financial year. ODDO SEYDLER BANK AG, Frankfurt, was the sole lead manager of the capital measures.
About WILEX and Heidelberg Pharma
WILEX AG is a biopharmaceutical company which discontinued all clinical development activities at its Munich site and now exercises a holding function as the Group parent. Research and development focus on the operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances the development of the innovative platform technology for antibody drug conjugates (ADC technology) and provides pre-clinical drug discovery and development services. WILEX has the diagnostic and therapeutic drug candidates REDECTANE® and RENCAREX®, which are available for out-licensing and further development in Phase III for external partners. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at http://www.wilex.com/.
Tel.: +49 (0)89-41 31 38-29
Grillparzerstr. 18, 81675 Munich, Germany
MC Services AG
Katja Arnold (CIRO)
Executive Director & Partner
Tel.: +49-89-210 228-40
Mobil: +49 160 9360 3022
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward- looking statements to reflect future events or developments.